L. Lacomblez

Publications282
h-index57
Citations13,604
Highly Influential Citations634
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • V. Meininger
  • 360 Publications, 18,375 Citations
  • B. Miller
  • 1,021 Publications, 81,833 Citations
  • F. Salachas
  • 165 Publications, 7,750 Citations
  • J. Hodges
  • 989 Publications, 70,812 Citations
  • Publications
  • Influence
TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis
Recently, TDP-43 was identified as a key component of ubiquitinated aggregates in amyotrophic lateral sclerosis (ALS), an adult-onset neurological disorder that leads to the degeneration of motor… Expand
  • 1,298
  • 132
A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.
BACKGROUND Amyotrophic lateral sclerosis is a progressive motor neuron disease for which there is no adequate treatment. Some research suggests that the excitatory amino acid neurotransmitter… Expand
  • 1,771
  • 42
Parkinson’s disease and sleepiness: An integral part of PD
ObjectiveTo investigate the potential causes of excessive daytime sleepiness in patients with PD—poor sleep quality, abnormal sleep–wakefulness control, and treatment with dopaminergic agents.… Expand
  • 468
  • 35
Decreased awareness of cognitive deficits in patients with mild dementia of the Alzheimer type
To study the unawareness of cognitive deficits in patients with mild dementia of Alzheimer type (DAT).
  • 210
  • 29
TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration
TDP‐43 (TAR‐DNA binding protein) aggregates in neuronal inclusions in motoneuron disease (MND), as well as in frontotemporal lobar degeneration (FTLD) and FTLD associated with MND (FTLD‐MND).… Expand
  • 272
  • 24
Dose-ranging study of riluzole in amyotrophic lateral sclerosis
Abstract Summary Background Amyotrophic lateral sclerosis (ALS) is a progressive disease with no effective treatment. In an initial study, riluzole decreased mortality and slowed muscle-strength… Expand
  • 1,031
  • 19
Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy.
This article reports the severity and profile of neuropsychological impairment on a prevalent cohort of patients with a clinical diagnosis of either multiple system atrophy (n=372) or progressive… Expand
  • 196
  • 14
  • PDF
SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype–phenotype correlations
Background Mutations in SOD1, ANG, VAPB, TARDBP and FUS genes have been identified in amyotrophic lateral sclerosis (ALS). Methods The relative contributions of the different mutations to ALS were… Expand
  • 251
  • 13
  • PDF
Diffusion tensor imaging and voxel based morphometry study in amyotrophic lateral sclerosis: relationships with motor disability
The aim of this study was to investigate the extent of cortical and subcortical lesions in amyotrophic lateral sclerosis (ALS) using, in combination, voxel based diffusion tensor imaging (DTI) and… Expand
  • 136
  • 13
  • PDF
Neural correlates of cognitive impairment in posterior cortical atrophy.
With the prospect of disease-modifying drugs that will target the physiopathological process of Alzheimer's disease, it is now crucial to increase the understanding of the atypical focal… Expand
  • 144
  • 11
  • PDF